Search
Now showing items 1-10 of 59
Emerging biomarkers for PD-1 pathway cancer therapy.
(2017-01)
The field of immuno-oncology has witnessed unprecedented success in recent years, with several PD=1 and PD-L1 inhibitors obtaining US FDA registration and breakthrough drug therapy designation in multiple tumor types. ...
Predicting development of ipilimumab-induced hypophysitis: utility of T4 and TSH index but not TSH.
(SPRINGER, 2020-05-24)
PURPOSE: Ipilimumab, a monoclonal antibody inhibiting CLTA-4, is an established treatment in metastatic melanoma, either alone or in combination with nivolumab, and results in immune mediated adverse events, including ...
Developing biomarker guided treatments for colorectal cancer
(Institute of Cancer Research (University Of London), 2021-09-30)
Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer.
(2017-02-09)
Background NeoSphere showed significantly higher pathologic complete response (pCR) with neoadjuvant pertuzumab, trastuzumab, and docetaxel compared with trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab ...
Precision Medicine in Pancreatic Disease-Knowledge Gaps and Research Opportunities: Summary of a National Institute of Diabetes and Digestive and Kidney Diseases Workshop.
(2019-11)
A workshop on research gaps and opportunities for Precision Medicine in Pancreatic Disease was sponsored by the National Institute of Diabetes and Digestive Kidney Diseases on July 24, 2019, in Pittsburgh. The workshop ...
Evaluating MRI biomarkers of tumour hypoxia
(Institute of Cancer Research (University Of London), 2020-12-31)
Tumour hypoxia is associated with resistance to radiotherapy and chemotherapy, and represents a major challenge in the treatment of head and neck squamous cell carcinoma (HNSCC). Non-invasive imaging methods to repeatedly ...
Immune and muli-omic profiling for molecular classification and biomarker discovery in soft tissue sarcoma
(Institute of Cancer Research (University Of London), 2020-02-29)
Soft tissue sarcomas (STS) are a group of over 50 rare cancers of mesenchymal origin. Classification of STS is primarily based on histological characteristics of tumours. Novel biomarkers are required that account for the ...
Diagnostic Utility of Molecular and Imaging Biomarkers in Cytological Indeterminate Thyroid Nodules.
(2018-04)
Indeterminate thyroid cytology (Bethesda III and IV) corresponds to follicular-patterned benign and malignant lesions, which are particularly difficult to differentiate on cytology alone. As ~25% of these nodules harbor ...
Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Diffuse Large B-Cell Lymphoma: An Individual Patient-Level Analysis of Multiple Randomized Trials (SEAL).
(2018-09)
Purpose Overall survival (OS) is the definitive and best-established primary efficacy end point to evaluate diffuse large B-cell lymphoma (DLBCL) therapies, but it requires prolonged follow-up. An earlier end point assessed ...
Targeting the Human Epidermal Growth Factor Receptors with Immuno-PET: Imaging Biomarkers from Bench to Bedside.
(SOC NUCLEAR MEDICINE INC, 2016-07-01)